Your browser doesn't support javascript.
loading
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Martin, Thomas G; Moreau, Philippe; Usmani, Saad Z; Garfall, Alfred; Mateos, María-Victoria; San-Miguel, Jesús F; Oriol, Albert; Nooka, Ajay K; Rosinol, Laura; Chari, Ajai; Karlin, Lionel; Krishnan, Amrita; Bahlis, Nizar; Popat, Rakesh; Besemer, Britta; Martínez-López, Joaquín; Delforge, Michel; Trancucci, Danielle; Pei, Lixia; Kobos, Rachel; Fastenau, John; Gries, Katharine S; van de Donk, Niels W C J.
Afiliação
  • Martin TG; University of California San Francisco, San Francisco, CA. Electronic address: Tom.Martin@ucsf.edu.
  • Moreau P; Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France.
  • Usmani SZ; Levine Cancer Institute/Atrium Health, Charlotte, NC.
  • Garfall A; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Mateos MV; University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain.
  • San-Miguel JF; Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain.
  • Oriol A; Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • Nooka AK; Winship Cancer Institute, Emory University, Atlanta, GA.
  • Rosinol L; Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Chari A; Mount Sinai School of Medicine, New York, NY.
  • Karlin L; Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
  • Krishnan A; City of Hope Comprehensive Cancer Center, Duarte, CA.
  • Bahlis N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada.
  • Popat R; University College London Hospitals, NHS Foundation Trust, London, UK.
  • Besemer B; University of Tuebingen, Tuebingen, Germany.
  • Martínez-López J; Haematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, CNIO, CIBERONC, Madrid, Spain.
  • Delforge M; Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
  • Trancucci D; Janssen Research & Development, Raritan, NJ.
  • Pei L; Janssen Research & Development, Raritan, NJ.
  • Kobos R; Janssen Research & Development, Raritan, NJ.
  • Fastenau J; Janssen Research & Development, Raritan, NJ.
  • Gries KS; Janssen Research & Development, Raritan, NJ.
  • van de Donk NWCJ; Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Clin Lymphoma Myeloma Leuk ; 24(3): 194-202, 2024 03.
Article em En | MEDLINE | ID: mdl-38052709
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_cobertura_universal Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_cobertura_universal Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Lymphoma Myeloma Leuk Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article